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Introduction: High-frequency oscillation ventilation (HFOV) is regarded as particularly lung protective. Recently,
HFOV has been shown to be not beneficial for acute respiratory distress syndrome (ARDS) patients in general.
Due to its special physical effects, it could be beneficial, however, in inhomogeneous ARDS. This study evaluates
the effect of HFOV on PaCO2 removal in hypercapnic patients with ARDS of pulmonary origin.
Methods: Between October 2010 and June 2014 patients with ARDS of pulmonary origin with PaO2/FiO2 ratio
>60 mmHg, but respiratory acidosis (pH <7.26) under optimized protective ventilation were switched to HFOV,
using moderate airway pressure (adopting the mean airway pressure of the prior ventilation). Data from these
patients were analyzed retrospectively; PaCO2 and pH before, 1 h and 24 h after the start of HFOV were compared.
Results: Twenty-six patients with PaO2/FiO2 ratio 139 ± 49 and respiratory acidosis (PaCO2 68 ± 12 mmHg) were put on
HFOV after 17 ± 22 h of conventional ventilation. Mean airway pressure was 19 cm H2O (15 to 28). PaCO2 decreased
significantly: after 1 hour the mean difference was −14 ± 10 mmHg; P <0.01 and after 24 hours −17 ± 12 mmHg; P <0.01;
n = 24. CO2 clearance improved in all but two patients; in those, extracorporeal lung support was initiated. Oxygenation
remained unchanged after 1 h and slightly increased after 24 h. No complications related to HFOV were observed.
Twenty-two patients improved and could be weaned from HFOV. Twenty patients (77%) were alive on day 30.
Conclusions: HFOV could be a useful alternative in patients with ARDS of pulmonary origin with hypercapnic failure of
lung-protective conventional ventilation.Introduction
High-frequency oscillation ventilation (HFOV) has been
considered to be particularly lung-protective because -
compared with conventional ventilation - its physical
characteristics may allow better avoidance of both
overinflation and recurring alveolar derecruitment
[1,2]. Technically, oscillations of 3 to 15 Hz are
superimposed onto a constant airway pressure applied
via a customary cuffed tracheal tube. The resulting
tidal volumes (Vts) often remain below the airway dead
space. Effective alveolar ventilation can be achieved
nonetheless by physical mechanisms that are explained
elsewhere [3-5].* Correspondence: sigrun.friesecke@uni-greifswald.de
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unless otherwise stated.Two recent multicenter studies could not show a
survival benefit in adult acute respiratory distress syndrome
(ARDS) patients with unselected etiologies of ARDS [6,7].
Therefore, HFOV has so far no place in routine care for
ARDS. In special circumstances however, HFOV may be
beneficial, mostly as a rescue therapy in oxygenation failure
[2,8-10]. A substantial improvement in oxygenation [7,11]
and the safety of HFOV have been shown [12,13] even
though barotrauma is reported in a substantial number of
patients [9,14].
ARDS of pulmonary origin (ARDSpulm) is defined as
ARDS caused by an insult primarily affecting the lungs
[15]. Compared to ARDS of extrapulmonary origin, in
which a hematogeneous insult leads to a diffuse damage
with uniform distribution, ARDSpulm shows a distinct
computed tomography (CT) morphology with a multifocal
and asymmetric involvement [16]. Such inhomogeneously
damaged lungs with very different local compliances areal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ventilation [17]. Complete recruitment often is not possible
using conventional ventilation without risk of ventilator-
induced lung injury [18]. With conventional ventilation,
normally compliant alveoli are exposed to a significant risk
of volutrauma due to preferential airflow into these
segments [3]. As HFOV is more homogeneous and less
dependent on different regional compliances [19], it should
be especially advantageous in cases of inhomogeneous
pulmonary damage.
We hypothesize a benefit in patients with ARDSpulm
and hypercapnic failure of lung-protective conventional
ventilation. Ventilatory failure has been suggested as
an indication for HFOV [20] but data supporting this
alternative are scarce. The main goal is to evaluate
CO2 removal with HFOV in patients with ARDS with
acceptable oxygenation but hypercapnic failure of conven-
tional ventilation. We hypothesize that efficient CO2
removal could be achieved with HFOV in these patients.
Materials and methods
This observational study was done at the medical ICU of
the University Medicine of Greifswald between October
2010 and June 2014. The study was approved by the
institutional ethics committee at Ernst Moritz Arndt
University of Greifswald, who waived the need for
informed consent.
Included were all patients with ARDS (novel definition
[21], partly adapted retrospectively) of pulmonary origin
who received HFOV for respiratory acidosis under lung-
protective ventilation with tidal volumes of 6 ml per kg
of ideal body weight. HFOV was begun in the case of
pH <7.26. If ARDS was accompanied by a cor pulmonale
with hemodynamic instability necessitating catechol-
amines, the threshold for change to HFOV was a milder
hypercapnia (pH <7.30). Cor pulmonale was diagnosed
by bedside echocardiography (routinely done in every
ARDS patient in the initial course) if dilatation of the
right ventricle (in apical four-chamber view basal right
ventricular diameter ≥ left ventricular diameter) and re-
duced right ventricular contractility were present (tricuspid
annular plane systolic excursion <15 mm). ARDSpulm was
diagnosed if a primary pulmonary insult was obvious
(as in pneumonia or aspiration) or an inhomogeneous
pulmonary CT pattern was evident without a pathogenetic
role of systemic inflammation. Patients were excluded
from the analysis, if the arterial partial pressure of oxygen/
fraction of inspired oxygen (PaO2/FiO2) ratio was
lower than 60 mmHg, necessitating rescue procedures
to improve oxygenation. HFOV was not used if therapy
was to be limited because of terminal illness or patient’s
advance directive, or if HFOV was contraindicated
because of severe airway obstruction or intracranial
hypertension [20].Prior to HFOV in all study patients, pressure-controlled
conventional ventilation (using a standard ventilator
(Evita™, Fa Dräger, Lübeck, Germany)) had been optimized
in the following way: determination of the positive end-
expiratory pressure (PEEP) optimum for oxygenation by a
PEEP trial, adjustment of inspiratory pressure to achieve
Vts not larger than 6 ml per kg of ideal body weight,
and maximizing respiratory frequency leaving no zero
expiratory flow time, but allowing complete expiration.
The PEEP trial was performed with a stepwise increase of
PEEP level (steps of 2 cmH2O) and evaluation of PaO2
and arterial partial pressure of carbon dioxide (PaCO2) at
every step. According to the approach proposed by Rouby
to reduce the risk of overinflation in patients with focal
loss of aeration, we started with PEEP 5 to 8 cmH2O [18].
Patients were sedated according to the local standard
operating procedure with propofol and sufentanyl. Muscle
relaxants were applied in case of impossibility to achieve
patient-ventilator synchrony.
The ICU team has several years’ experience with
HFOV. The ventilator used was Vision alpha™, Novalung
GmbH, Heilbronn, Germany. Frequency was initially set
to a frequency of 5 Hz. A higher start frequency was
chosen if a too rapid PaCO2 decrease was a concern, that
is in case of severe acidosis with pH <7.15. The resulting
cycle volume is automatically 90% of the maximal
frequency-dependent cycle volume (at 5 Hz 315 ml); it
can manually be increased up to 100%. This was done in
case of persisting hypercapnia at a frequency of 5 Hz. A
cuff leak was not used. Inspiratory to expiratory ratio (I:E)
is fixed at 1:1. To optimize lung protection, HFOV
frequency was increased in the case of reaching a normal
pH and was adjusted to the greatest value that still resulted
in an arterial pH <7.29 [22]. Blood gases were checked after
the first 30 and 60 minutes of HFOV, then at least two
times per shift. Mean airway pressure (mPaw) was set equal
to the actual mPaw of the conventional ventilation. As
oxygenation was not critically impaired and there was a
lower recruitment potential and a higher risk of volutrauma
in inhomogeneous ARDS, we refrained from increasing
mPaw when changing to HFOV. Sedation was continued in
the above mentioned manner. A chest X-ray was taken
within 24 hours to rule out overinflation [23].
Outcome parameter was the change in PaCO2 after 1
and 24 hours of HFOV, compared to PaCO2 pre-HFOV.
Statistical analysis was done using paired t test. Values
are given as mean ± standard deviation. Further data
were collected including etiology of respiratory failure,
simplified acute physiology score II (SAPS II), duration
and setting of pre-HFOV ventilation and of HFOV, 30-day
mortality and HFOV-related adverse events. Required
minute ventilation (MV) for normal PaCO2 (MV x
PaCO2/40) was calculated additionally as surrogate for
dead space [24].
Table 2 Blood gas analyses before and during











PaCO2 (mmHg) 67.6 ± 12.3 53.9 ± 13.7 <0.001 50.4 ± 17.3 <0.001
pH 7.20 ± 0.069 7.28 ± 0.095 <0.001 7.34 ± 0.052 <0.001
PaO2/FiO2
(mmHg)
139 ± 49 125 ± 50 0.17 155 ± 52 0.16
P values of paired t test. Two patients receiving extracorporeal lung support
were omitted from 24-hour analysis. Values are given as mean ± standard
deviation. PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial
partial pressure of oxygen; FiO2, fraction of inspired oxygen.
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Eighty-three ARDS patients were treated from October
2010 at this ICU. Twenty-six patients received HFOV
because of hypercapnia, most with moderate ARDS.
Baseline data are recorded in Table 1.
HFOV was begun 17 ± 22 h after start of mechanical
ventilation. Initially, a frequency of 5 to 6 Hz was used
and an mPaw between 15 and 28 cmH2O (median
18 cmH2O). In one patient, pressure had to be reduced
because of radiographic signs of overinflation.
After the first hour of HFOV, PaCO2 was significantly
reduced (−14 mmHg, P <0.01; see Table 2). Reduction of
PaCO2 was seen in all but two patients in whom PaCO2
did not improve despite increasing cycle volume.
They received additional extracorporeal lung support
(iLA™ membrane ventilator, Novalung GmbH, Heilbronn,
Germany). These patients were therefore omitted from the
24-hour analysis of PaCO2. In the remaining 24 patients, aTable 1 Baseline data and concomitant therapy
Number of patients 26
Age (years) 63 ± 16
Male sex 16 (61.5%)







Granulomatosis with polyangiitis 1 (3.8%)
Extrinsic allergic alveolitis 1 (3.8%)
Bronchiolitis obliterans with organizing pneumonia 1 (3.8%)
Unknown origin 1 (3.8%)
Ventilation prior to HFOV (all BIPAPassist)
Duration (hours) 17 ± 22
PEEP (cmH2O) 12 [6-20]
Inspiratory pressure (cmH2O) 27 [18-36]
Tidal volume (ml) 455 ± 108
Tidal volume (ml/kg of ideal body weight) 6.6 ± 0.9
Minute ventilation (l/min) 9.6 ± 1.8
Frequency 22 ± 6
MV x PaCO2/40 (l/min) 15.6 ± 3.0
Proning 6 (23%)
Values are given as number (percentage), mean ± standard deviation, or
median [range], respectively; MV x PaCO2/40, required minute ventilation
for normal PaCO2. SAPS II, simplified acute physiology score II; ARDS, acute
respiratory distress syndrome; HFOV, high-frequency oscillation ventilation;
PEEP, positive end-expiratory pressure; MV, minute ventilation; PaCO2, arterial
partial pressure of CO2.significant decrease of PaCO2 persisted (−17 mmHg after
24 h; P <0.01), see Table 2. In another patient, the
improved CO2 clearance could not be sustained by
HFOV, and extracorporeal lung support had to be applied
7 days later.
After 24 hours, HFOV frequency had been adjusted to
6 Hz (median, range 5 and 10 Hz); in six patients
no increase of frequency had been possible, in eleven
patients frequency after 24 h was 6 Hz, in seven
patients a frequency of greater than 6 could be chosen.
mPaw after 24 h was between 15 and 25 cmH2O (median
19 cmH2O). Oxygenation remained unchanged after 1
and 24 h (Table 2).
Twenty-two of the 23 patients without extracorporeal
lung assist (ECLA) improved and could be switched
back to conventional ventilation after 177 (±94) hours.
One patient died on HFOV. Twenty patients (77% of the
whole cohort) were alive on day 30, 15 (58%) survived to
hospital discharge. Six patients died from extrapulmonary
reasons, five from nonresolving lung failure. Complications
related to HFOV were not observed throughout the study
period. In particular, there were no radiographic or clinical
signs of barotrauma in any patient.
Discussion
In ARDSpulm with hypercapnic failure of conventional
ventilation, HFOV - implemented early in the course
and refraining from increasing mPaw - could effectively
remove CO2. This was observed in 92% of the patients
in this case series. In children, an effective CO2 removal
has been demonstrated by HFOV [25]. Several studies in
adults, however, found PaCO2 increasing or unchanged
during HFOV [12,13,26-28]. Lubnow et al. used an
algorithm with initiating HFOV only if pH >7.25 in
persistent severe ARDS, and ECLA if <7.25 [29]. The
two recent meta-analyses again showed no significant
difference in ventilation efficiency or PaCO2 [11,30].
So in general, HFOV is not seen as a tool for ventilation
failure. In fact, the combination with extracorporeal CO2
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HFOV specifically for CO2 removal in patients with
ARDSpulm. HFOV has been considered to be a very
lung-protective mode. This is expected to be especially
relevant for inhomogeneous lung injury in ARDSpulm
with consolidation adjacent to normally compliant alveoli,
which in this setting may experience cyclic volutrauma
with conventional ventilation due to preferential airflow
into these segments [3]. HFOV due to its special mode
avoids this drawback. Furthermore, in this subset of
mainly focal ARDS, there is lower recruitment potential
[33] and lower PEEP levels are recommended [18],
whereas higher PEEP may propagate an infection or lead
to overdistension [34]. Therefore, we decided not to
increase the mPaw under conventional ventilation.
This is in contrast to the application in recent studies
[6,7,12]. Oxygenation did not deteriorate despite leaving
mPaw unchanged. Barotrauma did not occur in this
setting of HFOV, but has been reported in substantial
proportions of patients in previous studies [9,14,22].
Compared to most studies, which did not show an
improvement in PaCO2, there are some differences:
the patients in this study mainly had moderate ARDS;
whereas others dealt with severe ARDS [9,27,35]. As
oxygenation was acceptable under conventional ventila-
tion, we could refrain from the rather high distension
pressures that are frequently inevitable in hypoxemic
ARDS. Higher airway pressures have been shown to be as-
sociated with lower CO2 clearance [9], whereas some data
suggest that lower mPaws on HFOV may result in more
effective ventilation. In patients with chronic obstructive
pulmonary disease (COPD) using mPaw in the same range
as we did, a sufficient CO2 removal was achieved
[36]. Two further studies are in line with our results:
Fessler et al. demonstrated a sufficient CO2 clearance
in patients in whom HFOV was initiated partly for
ventilation failure [22]. Camparota reported a significant
decrease in PaCO2 in severe ARDS, predominantly of
extrapulmonary origin, with a greater effect in patients
with more severe disease and lower respiratory system
compliance. They supposed that extrapulmonary origin -
implying more recruitment potential - was an important
factor for the response to HFOV [10]. In contrast, we
found a significant effect in moderate ARDSpulm with
more severe pre-HFOV hypercapnia.
Why use HFOV at all after the most recent studies?
Two recent studies [6,7] did not show a mortality benefit
for HFOV in ARDS, as did two recent meta-analyses
[11,30]. These results do not preclude a benefit of this
ventilation mode in special patients or circumstances
[37]. The use in oxygenation failure remains an indication.
Furthermore, HFOV was used successfully in combination
with extracorporeal membrane oxygenation (ECMO)
in posttraumatic ARDS to recruit a lung with minimalcompliance [38]. We used HFOV in patients with
respiratory acidosis under protective ventilation. We im-
plemented HFOV early in the course when initial optimi-
zations of ventilation resulted in pH <7.26. This pH
threshold for intervention is in accordance to other differ-
ent studies [29,39] and a consensus article [20].
Initiation of HFOV might not have been the only
possibility in the reported patients. Those with pH ≥7.20
under ventilation with Vt 6 ml/kg could have remained
on conventional ventilation. There are, however, con-
cerns regarding adverse effects of hypercapnia [40,41].
Furthermore, in focal ARDS even a Vt of 6 ml per kg
may result in hyperinflation [34,42]. As Vt was already at
the higher margin, we aimed to minimize hypercapnia
with an alternative ventilation technique, which is
supposed to be more protective [1]. With pH <7.20,
conventional ventilation could have been complemented
by extracorporeal CO2 elimination, which was regarded
as more invasive and therefore reserved as a fallback
solution. We actually used ECLA when HFOV failed to
improve CO2 clearance. In a similar way, Lubnow et al.
treated their patients with ARDS with initial HFOV [29].
There are several limitations of this study: this is a
retrospective analysis of a small sample size. With
HFOV far away from being a standard procedure, we
report our experience in a clearly defined subgroup of
patients with ARDS, including all consecutive ones in
a definite period. Furthermore, we did not examine
parameters of pulmonary stress or inflammation, so
we cannot draw conclusions regarding benefit of this
alternative strategy.
Conclusions
In a high percentage of ARDSpulm with hypercapnic
failure of lung-protective conventional ventilation, we
found effective CO2 removal by HFOV instituted
early in the course and using distending pressures
equal to that of the preceding conventional ventila-
tion. These patients may benefit from HFOV as an
especially lung-protective strategy. The role of HFOV
in hypercapnia management facing different options,
including extracorporeal techniques, remains to be
determined.
Key messages
 Protective ventilation in ARDS may lead to severe
respiratory acidosis necessitating an alternative or
additional approach.
 With HFOV a more effective CO2 elimination may
be achievable compared to conventional protective
ventilation in ARDSpulm.
 HFOV may be an alternative in hypercapnic failure
of protective ventilation in patients with ARDS.
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